Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 5/2007

01-12-2007 | Review

Clinical trials in severe sepsis with drotrecogin alfa (activated)

Author: Pierre-François Laterre

Published in: Critical Care | Special Issue 5/2007

Login to get access

Abstract

Drotecogin alfa (activated; DrotAA) was approved in 2001 by the US Food and Drug Administration for the treatment of patients with severe sepsis who are at high risk for death. The European Agency for the Evaluation of Medical Products also recommended that DrotAA could be administered to patients with severe sepsis and multiple organ dysfunction when added to the best standard care. Following the initial publication of the PROWESS (Protein C Worldwide Evaluation in Severe Sepsis) findings, multiple subgroup analyses supported the need for additional studies to explore the various hypotheses raised by this study. This review discusses all large clinical trials exploring the efficacy and safety of DrotAA and proposes recommendations for the use of DrotAA in severe sepsis.
Literature
1.
Bernard GR, Ely EW, Wright TJ, Fraiz J, Stasek JE, Russell JA, Mayers I, Rosenfeld BA, Morris PE, Yan SB, et al: Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med. 2001, 29: 2051-2059. 10.1097/00003246-200111000-00003.CrossRefPubMed
2.
Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely W, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001, 344: 699-709. 10.1056/NEJM200103083441001.CrossRefPubMed
3.
Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, Johnson G, Bernard GR: Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med. 2003, 31: 834-840. 10.1097/01.CCM.0000051515.56179.E1.CrossRefPubMed
4.
Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, Vincent JL, Macias WL, Bernard GR: Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med. 2003, 31: 12-19. 10.1097/00003246-200301000-00002.CrossRefPubMed
5.
Ely EW, Angus DC, Williams MD, Bates B, Qualy R, Bernard GR: Drotrecogin alfa (activated) treatment of older patients with severe sepsis. Clin Infect Dis. 2003, 37: 187-195. 10.1086/375775.CrossRefPubMed
6.
Opal SM, Garber GE, LaRosa SP, Maki DG, Freebairn RC, Kinasewitz GT, Dhainaut JF, Yan SB, Williams MD, Graham DE, et al: Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). Clin Infect Dis. 2003, 37: 50-58. 10.1086/375593.CrossRefPubMed
7.
Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, Sollet JP, Maki DG, Bates B, Yan SB, Dhainaut JF: Severe community-acquired pneumonia as a cause of severe sepsis: Data from the PROWESS study. Crit Care Med. 2005, 33: 952-961. 10.1097/01.CCM.0000162381.24074.D7.CrossRefPubMed
8.
Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, Laterre PF, Vincent JL, Bernard G, van Hout B: Cost effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med. 2003, 31: 1-11. 10.1097/00003246-200301000-00001.CrossRefPubMed
9.
Laterre PF, Levy H, Clermont G, Ball DE, Garg R, Nelson DR, Dhainaut JF, Angus DC: Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial. Crit Care Med. 2004, 32: 2207-2218.PubMed
10.
Angus DC, Laterre PF, Helterbrand J, Ely EW, Ball DE, Garg R, Weissfeld LA, Bernard GR, PROWESS Investigators: The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. Crit Care Med. 2004, 32: 2199-2206. 10.1097/01.CCM.0000114816.62331.08.CrossRefPubMed
11.
Vincent JL, Bernard GR, Beale R, Doig C, Putensen C, Dhainaut JF, Artigas A, Fumagalli R, Macias W, Wright T, et al: Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med. 2005, 33: 2266-2277. 10.1097/01.CCM.0000181729.46010.83.CrossRefPubMed
12.
Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, Francois B, Guy JS, Brückmann M, Rea-Neto A, et al: Drotecogin alfa (activated) for adult patients with severe sepsis and a low risk of death. N Engl J Med. 2005, 353: 1332-1341. 10.1056/NEJMoa050935.CrossRefPubMed
13.
Levi M, Levy M, Williams MD, Douglas I, Artigas A, Antonelli M, Duncan W, Janes J, Booth FV, Wang D, et al: Prophylactic heparin in patients with severe sepsis treated with drotecogin alfa (activated). Am J Respir Crit Care Med. 2007, 176: 483-490. 10.1164/rccm.200612-1803OC.CrossRefPubMed
14.
Barton P, Kalil AC, Nadel S, Goldstein B, Okhuysen-Cawley R, Brilli RJ, Takano JS, Martin LD, Quint P, Yeh TS, et al: Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. Pediatrics. 2004, 113: 7-17. 10.1542/peds.113.1.7.CrossRefPubMed
15.
Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA, Levy H, Angle R, Wang D, et al: Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet. 2007, 369: 836-843. 10.1016/S0140-6736(07)60411-5.CrossRefPubMed
16.
Kanji S, Perreault MM, Chant C, Williamson D, Burry L: Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study. Intensive Care Med. 2007, 33: 517-523. 10.1007/s00134-007-0555-9.CrossRefPubMed
17.
Bertolini G, Rossi C, Anghileri A, Livigni S, Addis A, Poole D: Use of drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey. Intensive Care Med. 2007, 33: 426-434. 10.1007/s00134-007-0554-x.CrossRefPubMed
18.
Warren HS, Suffredini AF, Eichacker PQ, Munford RS: Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med. 2002, 347: 1027-1030. 10.1056/NEJMsb020574.CrossRefPubMed
19.
Mackenzie AF: Activated protein C: do more survive?. Intensive Care Med. 2005, 31: 1624-1626. 10.1007/s00134-005-2829-4.CrossRefPubMed
20.
Carlet J: Prescribing indications based on successful clinical trials in sepsis: a difficult exercise. Crit Care Med. 2006, 34: 525-529. 10.1097/01.CCM.0000198329.85851.8E.CrossRefPubMed
21.
Macias WL, Vallet B, Bernard GR, Vincent JL, Laterre PF, Nelson DR, Derchak PA, Dhainaut JF: Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis. Crit Care Med. 2004, 32: 2385-2391. 10.1097/01.CCM.0000147440.71142.AC.CrossRefPubMed
Metadata
Title
Clinical trials in severe sepsis with drotrecogin alfa (activated)
Author
Pierre-François Laterre
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Critical Care / Issue Special Issue 5/2007
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc6156

Other articles of this Special Issue 5/2007

Critical Care 5/2007 Go to the issue

Review

Practical aspects of treatment with drotrecogin alfa (activated)

Introduction

Introduction: severe sepsis and drotrecogin alfa (activated)

Review

The protein C pathway: implications for the design of the RESPOND study

Review

Diagnosis and treatment of severe sepsis

Review

The safety profile of drotrecogin alfa (activated)

Review

Recombinant human activated protein C: current insights into its mechanism of action